Nitric Oxide (NO) and NO Synthases (NOS)-Based Targeted Therapy for Colon Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality globally, with current therapies often proving insufficient.
• Nitric oxide (NO), a reactive gas, and its producing enzymes (nitric oxide synthases, NOS) play complex roles in cancer biology.
• NO exhibits paradoxical effects in cancer, promoting tumor growth at endogenous levels while exerting cytotoxic effects when supplied exogenously.

Purpose of the Study:

• To review the multifaceted roles of NO-mediated signaling in colorectal cancer hallmarks.
• To summarize the clinical applications, limitations, and future directions of NO and NOS-targeted therapies for CRC.

Main Methods:

• Literature review of studies on nitric oxide and nitric oxide synthases in colorectal cancer.
• Analysis of signaling pathways (e.g., Wnt/β-catenin, ERK) influenced by NO in CRC.
• Evaluation of clinical trial data for NO-donating agents and NOS inhibitors in CRC treatment.

Main Results:

• Endogenous NO promotes colon cancer, while exogenous NO demonstrates anti-tumor activity.
• NO is a key mediator in CRC-associated pathways like Wnt/β-catenin and ERK, influencing initiation, metastasis, and resistance.
• Inducible NOS (iNOS) is overexpressed in inflammatory colon cancers, making iNOS inhibitors a potential targeted therapy.

Conclusions:

• NO/NOS pathways represent promising therapeutic targets for colorectal cancer regulation.
• NO donors and NOS inhibitors show potential but face clinical limitations that require further investigation.
• Future research should focus on optimizing NO/NOS-based therapies for improved clinical outcomes in CRC.